Xaira reported results from the Vega class of its X-Design models, which designed antibodies zero shot, with no data from earlier campaigns. Against its lead oncology target, XA-1, a single design pass produced a progressable binder in three weeks and a preclinical lead in seven, with 17 nM affinity to the human target. Against XA-4, a GPCR where library screening and llama immunization had both failed, a library of 60,000 designs yielded a cross reactive, developable antagonist that has moved into lead optimization.
Our readSuccess on a target that conventional discovery could not crack is the claim that matters, since speed on well characterized targets has been shown before. Xaira says a systematic assessment of X-Design will follow, and that is the data partners will want.